Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 140

Sort by

Sort Order Select

Journal Articles

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz, Angela Dispenzieri, Shaji K Kumar, Anita D'Souza, Anannya Patwari, Andrew J Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan Schönland, Suzanne Lentzsch, Eli Muchtar

Blood blood.2024025899.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Michael Rosenzweig, Yvonne Efebera, Efstathios Kastritis, Brandon Blue, Faizi Jamal, Monique C Minnema, Christopher Pericone, Sandra Vasey, Yuping Chen, Sonja Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Jessica Vermeulen, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2023-181953

Published: 2023

Journal Articles

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Blood (2023) 142 (Supplement 1): 3411.

https://doi.org/10.1182/blood-2023-190226

Published: 2023

Journal Articles

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Raphael E Szalat, Srikanth Talluri, Charlotte M Royer, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2023-178730

Published: 2023

Journal Articles

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

Vaishali Sanchorawala, Ashutosh D Wechalekar, Efstathios Kastritis, Giovanni Palladini, Stefan Schönland, Raymond Comenzo, Anita D'Souza, Jack Khouri, Victor Jimenez-Zepeda, Katherine Ingrid Sprinz, Heather Hao, Wenying Huang, Laura Governale Aubrey, Morie A. Gertz

Blood (2023) 142 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2023-174703

Published: 2023

Journal Articles

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

Maya Abdallah, Frances Arters, Jasmine Patel, Matthew Lefebvre, Camille V. Edwards, Adam Lerner, Fabio Petrocca, Vaishali Sanchorawala, Andrew Staron, John Mark Sloan, Raphael E Szalat

Blood (2023) 142 (Supplement 1): 7432.

https://doi.org/10.1182/blood-2023-187811

Published: 2023

Journal Articles

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Blood (2023) 142 (Supplement 1): 4784.

https://doi.org/10.1182/blood-2023-188115

Published: 2023

Journal Articles

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Cara Rosenbaum, Michaela Liedtke, Paul Christos, Hyemin Kim, Kathleen Pogonowski, Natalie Agudo, Bruna Barroso, Anthony Shelton, Samantha Reilly, Courtney Gadbois, John Mark Sloan, Vaishali Sanchorawala, Anita D'Souza

Blood (2023) 142 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2023-191133

Published: 2023

Journal Articles

Abnormal Global Longitudinal Strain Correlates with Amyloidogenic Light Chain-Induced Cardiac Dysfunction via Direct Myocardial Toxicity in Patients without Significant Amyloid Fibril Deposition

Grace M. Ferri, Josue Villegas Galaviz, Tinuola Ajayi, Richard Giadone, George J. Murphy, Andrew Staron, Frederick L. Ruberg, Vaishali Sanchorawala, Camille V. Edwards

Blood (2023) 142 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2023-182520

Published: 2023

Journal Articles

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Andrew Staron, Eric J Burks, Raphael E Szalat, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2023-190813

Published: 2023

Journal Articles

Factors Underlying Impaired Organ Recovery Despite a Deep Hematologic Response in Patients with Systemic AL Amyloidosis

Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2023-189956

Published: 2023

Journal Articles

Blood-Based Diagnostic Assay for λ Light Chain Amyloidosis through Quantification of an Amyloidogenicity-Indicating Neo-Epitope

Xin Jiang, Jianying Wang, Yao-Cheng Li, Alexander B Jackman, Hannah Flaherty, Imani Rogers, Eli Muchtar, Angela Dispenzieri, Brian H Spencer, Vaishali Sanchorawala, Tatiana Prokaeva, Richard Labaudiniere

Blood (2023) 142 (Supplement 1): 536.

https://doi.org/10.1182/blood-2023-175005

Published: 2023

Journal Articles

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

Karina Verma, Andrew Staron, Luke Zheng, Gheorghe Doros, Vaishali Sanchorawala

Blood (2023) 142 (Supplement 1): 6762.

https://doi.org/10.1182/blood-2023-179597

Published: 2023

Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

Blood (2023) 142 (14): 1208–1218.

https://doi.org/10.1182/blood.2022019406

Published: 2023

Includes: Supplemental data

Journal Articles

Daratumumab in AL amyloidosis

Ashutosh D. Wechalekar, Vaishali Sanchorawala

Blood (2022) 140 (22): 2317–2322.

https://doi.org/10.1182/blood.2021014613

Published: 2022

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10180–10181.

https://doi.org/10.1182/blood-2022-165512

Published: 2022

Journal Articles

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Vaishali Sanchorawala, Michael Rosenzweig, Christopher Pericone, Sandra Y. Vasey, Xiang Qin, Sonja Marie Kotoulek, Bart Vandael, Joana Duran, Samer Khaled, NamPhuong Tran, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 10163–10164.

https://doi.org/10.1182/blood-2022-163615

Published: 2022

Journal Articles

Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity

Camille V Edwards, Richard Giadone, Sabrina Ghosh, Gareth Morgan, Vaishali Sanchorawala, George J Murphy

Blood (2022) 140 (Supplement 1): 7127–7128.

https://doi.org/10.1182/blood-2022-167127

Published: 2022

Journal Articles

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Hans C. Lee, Vaishali Sanchorawala, Shirley D'Sa, Satheesh Chonat, Carlos M. de Castro

Blood (2022) 140 (Supplement 1): 13057–13058.

https://doi.org/10.1182/blood-2022-157219

Published: 2022

Journal Articles

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, Lawreen H Connors, Vaishali Sanchorawala

Blood (2021) 138 (Supplement 1): 155.

https://doi.org/10.1182/blood-2021-151804

Published: 2021

NARROW

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in a Diverse Patient Population with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Pooled Analysis of Safety from Birtamimab Phase 1-3 Studies in Patients with Light Chain (AL) Amyloidosis

When a Number Is Just a Number: Duffy-Null Blood Group Phenotype, Absolute Neutrophil Count, and Incidence of Neutropenic Fever and Chemotherapy Dose Reductions in Patients Treated for Plasma Cell Dyscrasias

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Abnormal Global Longitudinal Strain Correlates with Amyloidogenic Light Chain-Induced Cardiac Dysfunction via Direct Myocardial Toxicity in Patients without Significant Amyloid Fibril Deposition

Prospective Evaluation of Measurable Residual Disease (MRD) and Sustainability of the Response in Patients with Systemic AL Amyloidosis Treated with Daratumumab

Factors Underlying Impaired Organ Recovery Despite a Deep Hematologic Response in Patients with Systemic AL Amyloidosis

Blood-Based Diagnostic Assay for λ Light Chain Amyloidosis through Quantification of an Amyloidogenicity-Indicating Neo-Epitope

Systemic AL Amyloidosis in Patients Younger Than 40 Years of Age: Clinical Presentation and Outcomes

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Daratumumab in AL amyloidosis

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius

Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only